Background The importance of tocolysis has been discussed extensively. Beta-2 adrenoceptor agonistic drugs like ritodrine have been the reference tocolytic drugs in most countries. Cardiovascular side-effects are frequent. Atosiban, a newer tocolytic drug, is a competitive antagonist of oxytocin and has fewer cardiovascular side effects. Although large studies exist, there is mainly subjective reporting of adverse reactions with a focus on blood pressure data. Objectives Evaluation of the acute effects of therapeutic doses of ritodrine and atosiban in comparison to placebo on central and peripheral blood pressures, central-to-peripheral blood pressure amplification and the augmentation index (AIx) in healthy non-pregnant female volunteers. Methods A double-blind, randomized, crossover trial was carried out in 20 healthy non-pregnant female volunteers. Hemodynamic measurements were performed under standardized conditions. Results At steady state, central and peripheral pressures did not differ from placebo in the atosiban group. During ritodrine -infusion, central SBP increased by 11% versus placebo (p = 0.012) and peripheral SBP by 10% (p = 0.004). In contrast to atosiban and placebo, blood pressure amplification was absent in the ritodrine group. While the AIx did not change in the atosiban group, with ritodrine, the AIx tended to decrease. Conclusions The present study shows the significant effects of ritodrine on the cardiovascular system. Atosiban has no significant effects and may be an appropriate alternative to tocolyticum, particularly in cardiovascularly complicated pregnancies.
Introduction
The importance of tocolysis has been discussed extensively [1] [2] [3] . Beta-2 adrenoceptor agonistic drugs such as ritodrine have been the reference tocolytic drugs in most countries [3, 4] . Their efficacy in prolonging pregnancy compared to placebo is proven, although no benefit in neonatal morbidity or mortality has been demonstrated [5] . Beta-mimetics are not highly selective and have many contraindications. Side effects are frequent due to beta-1 and beta-2 adrenoceptor agonistic cardiovascular effects. Even serious complications such as pulmonary edema and maternal death, though rare, have been reported [5] .
Atosiban, a newer tocolytic drug, is a competitive antagonist of oxytocin at uterine oxytocin receptors and has fewer cardiovascular side effects [6] . The 13th revision (08 July 2009) of the European Public Assessment Report (EPAR) on Tractocile® (atosiban) of the EMEA (European Medicines Agency) states that atosiban has the same effect as beta-mimetics on surrogate endpoints related to tocolysis. A better tolerability was observed, but there was no advantage in improving fetal and maternal outcome in comparison with beta-mimetics. This benefit of safety with atosiban has to be balanced against its cost [7, 8] . A study of Ferriols et al. [9] revealed that the costeffectiveness obtained with a protocol including ritodrine as first-choice drug was three times less than when atosiban was used. In pregnant women at high risk of developing acute pulmonary edema or cardiovascular disease (e.g., preeclampsia, cardiomyopathies, and cardiovascular syndromes), atosiban may be an appropriate alternative.
Although large studies using atosiban have been performed in both pregnant and nonpregnant groups [5, 8, [10] [11] [12] , there is mainly a subjective reporting of adverse reactions during infusion with a focus on peripheral blood pressure data.
Central blood pressure and pulse wave reflections may provide additional information regarding cardiovascular risk beyond peripheral blood pressure [13] [14] [15] . The central hemodynamic effects of tocolytic drugs have never been studied before. In this study, the acute effects of therapeutic doses of ritodrine and atosiban were evaluated on central and peripheral blood pressure, central-to-peripheral blood pressure amplification, and pulse wave reflections in healthy nonpregnant female volunteers.
Methods

Subjects
Twenty healthy nonpregnant female volunteers, either nonsmokers or smokers of ≤10 cigarettes per day with adequate nonuterine contraception were recruited from the local population. All participants gave written informed consent upon screening, which was organized within 2 weeks before the planned first drug administration. The subjects were apparently healthy (no cardiovascular diseases including arrhythmias, obstructive lung diseases, chronic kidney diseases, or diabetes mellitus). Breastfeeding women or women with a severe addiction were excluded.
Subjects were asked not to eat, smoke, and drink caffeinecontaining beverages for at least 3 h before and during the measurements. They also had to refrain from drinking alcohol for at least 10 h before measurements [16] .
Design
A double-blind, randomized, crossover trial was carried out at the Drug Research Unit Ghent of the Ghent University Hospital, Belgium. The study was approved by the Ethics Committee of Ghent University and conducted according to ICH Good Clinical Practice and in compliance with the Declaration of Helsinki (last amended in 2008 in Seoul).
Twenty female volunteers were given atosiban (Tractocile®, Ferring, Sweden) and placebo (glucose 5%) intravenously. Eight of them were randomly chosen to also get ritodrine (PrePar®, Eumedica, Belgium) in a single-blind way. The effects of drugs were compared after 95 min of infusion when kinetic steady state was reached for atosiban and ritodrine, which was 15 min after starting the highest dose (400 μg/min) of ritodrine. Hemodynamic measurements were done by one investigator with the subjects in supine position and under standardized conditions (derived from the Task Force III, clinical applications for arterial stiffness [16] ) in a temperature controlled room (22±1°C).
Medication
Medication and placebo were infused for 120 min at the left arm. Both atosiban and ritodrine were given with glucose 5% as vehicle. Atosiban was given at a constant dose of 300 μg/min at a constant infusion rate of 0.4 ml/min. Ritodrine was given in a dose escalation scheme starting with a dose of 100 μg/min gradually upgraded to a dose of 400 μg/min. The infusion rate varied with each dosing step (from 0.23 to 0.53 ml/min). Glucose 5% was given as placebo at a constant infusion rate of 0.4 ml/min. Dosing was based on previous studies using atosiban or ritodrine [3, [17] [18] [19] [20] and on the manufacturers' prescriptions. Over the course of each period, a total volume of 48 ml was infused.
Stopping criteria for dosing were a heart rate increase above 75% of the age-based maximum heart rate or blood pressure changes from baseline of more than 30 mmHg for systolic (SBP) and 15 mmHg for diastolic blood pressure (DBP) or a SBP above 180 mmHg or less than 90 mmHg and DBP more than 110 mmHg. If the subject suffered intolerable side effects, the infusion was also ended.
Measurements
Sphygmomanometry
Semi-recumbent brachial SBP and DBP and heart rate (HR) were recorded at the right upper arm with a validated semi-automated oscillometric device (OMRON 705IT, OMRON Healthcare, Hoofddorp, The Netherlands) [21] . Blood pressure and HR were recorded predose and at kinetic steady state. Mean arterial pressure (MAP) was calculated by adding 40% of the pulse pressure (PP) to the measured DBP [22] .
Applanation tonometry
Radial (RA) and carotid (CCA) pressure waveforms (PWFs) were recorded noninvasively with a Sphygmocor® applanation tonometry system (AtCor Medical, Sydney, Australia) [23] . To obtain local blood pressure at the CCA and RA, calibration of the recorded PWFs is required. Calibration is based on the validated assumption that DBP and MAP remain constant throughout the large arteries, while SBP and PP (the difference between SBP and DBP) change [24] . SBP at an arterial site (SBP X ) is SBP X =DBP+ PP X . Using our calibration method, PP at an arterial site (PP X ) can be calculated from PP at the brachial artery (PP BA ) as PP X ¼ PP BA Â FF BA =FF X [25] where FF BA and FF X are the form factors (FF) at the brachial artery and the target artery, respectively. FF X is defined as [26] : 
Augmentation index
Carotid augmentation index (AIx) was calculated from the carotid PWF as the ratio of the amplitude of the pressure wave above its systolic shoulder to the total pulse pressure [28] . Carotid AIx is a surrogate for aortic AIx and is considered to be an index of pressure wave reflection [29] . Since the AIx has an inverse, linear relationship with the HR, the AIx was corrected for HR [30] .
Data analysis
The median of three measurements was used for data analysis. Statistical analysis was done using SPSS version 15 (SPSS, Chicago, IL, USA).
A non-parametric Friedman test was run on data of the eight subjects who also received ritodrine to compare for repeated observations on the same subject. If statistically significant, this was followed by a Wilcoxon signed rank test for two-point comparison. Comparison between atosiban and placebo was done on all subjects using the Wilcoxon signed rank test. Demographic differences between study groups were analysed using the non-parametric Mann-Whitney U test.
Results
Demographic data
At study entry, the subgroup of 8 subjects also receiving ritodrine did not differ statistically from the whole group (n=20; Table 1 ). All subjects received the total amount of the planned dose, which was 300 μg/min for atosiban and 400 μg/min as the highest dose for ritodrine.
Central and peripheral blood pressure, and augmentation index Data for blood pressure and augmentation index are shown in Table 2 . With ritodrine, central SBP (at the CCA) increased by 13% versus placebo (P=0.012) and peripheral SBP (at the BA) increased by 12% (P=0.004). SBP at the radial artery, however, did not differ statistically from placebo. Compared to placebo, the DBP and MAP in the ritodrine group decreased by 19% (P=0.008) and 8% (P= 0.044), respectively. With atosiban, central and peripheral pressures did not differ from placebo.
With atosiban and placebo, the systolic pressure rises from the central CCA towards the peripheral RA. Although not statistically significant (P=0.180) from placebo and atosiban, with ritodrine there was a substantial loss of this systolic pressure amplification.
With ritodrine, the noncorrected AIx decreased (497%; P=0.005) and the AIx corrected for heart rate (AIx@HR75) tended to decrease (289%; P=0.225), while AIx did not change with atosiban.
Discussion
To the best of our knowledge, this is the first placebocontrolled, randomized study investigating the effects of ritodrine and atosiban on the central blood pressure, pressure wave reflection, and central-to-peripheral pressure amplification [31] [32] [33] [34] . The results from this study show that ritodrine has important and significant effects on the cardiovascular system, whereas atosiban shows no significant effects on the parameters we investigated.
Sphygmomanometer blood pressure
Similar effects have previously been reported. In studies with pregnant women, ritodrine caused a decrease in DBP (a drop of 4 and 7 mmHg from beginning to the end of the treatment [3, 7, 31] ). In studies with other beta-receptor agonists, DBP and MAP were reduced because of peripheral vasodilatation [35] [36] [37] . For atosiban, no significant fall in DBP occurred, which is consistent with earlier work [3, 32, 38, 39] .
Tonometry data
In a general population, the best estimate of the brachial form factor is 0.4 [22] . However this form factor can depend on different factors such as age [40] . We also observed that medication can substantially change the form factor at different arterial sites (RA: from 33.4 during placebo to 28.0 during ritodrine; CCA: from 43.4 during placebo to 28.7 during ritodrine). Therefore in the present study, the FF BA of each measurement was estimated using a procedure that expresses the FF BA as a (fixed) ratio of FF CCA and FF RA , circumventing the lack of brachial tonometry recordings.
The SBP CCA during ritodrine was higher and AIx was lower in comparison with those during atosiban and placebo. No other data on the effect of these tocolytic drugs on central SBP or AIx are available in the literature.
AIx has been proposed as an index of early wave reflections at the central arteries. Heart rate is a well-known determinant of AIx. But also after adjustment to a heart rate of 75 beats per minute (bpm), AIx tended to be lower during ritodrine than during atosiban or placebo, suggesting that ritodrine reduces wave reflections. As pulse wave reflections occur at changes in impedance (such as at arterial branches), the vasodilation with ritodrine may account for the decrease in arterial impedance and reduction in wave reflections. Studies [35, 37, 41] investigating effects of salbutamol (another beta-receptor agonist) on arterial stiffness revealed similar significant effects on AIx due to endothelial nitric oxide synthase (NOS)-dependent vascular relaxation.
In the present study, systolic pressure measured by applanation tonometry at the CCA was used as a noninvasive surrogate for cSBP [25] . The central blood pressure (cBP) may have a higher predictive value for cardiovascular events compared to traditional sphygmomanometer measurements since it is an important determinant of the left ventricular workload and coronary blood flow [14] . In contrast to SBP Systolic blood pressure, BP amplification blood pressure difference from CCA to RA, DBP diastolic blood pressure, MAP mean arterial pressure, HR heart rate, bpm beats per minute, AIx augmentation index, not corrected for heart rate, AIx@HR75 augmentation index at heart rate 75
All data are shown as mean ± standard deviation Twenty nonpregnant, healthy female volunteers received atosiban and placebo in a double-blind way, and eight of them also received ritodrine in a single-blind way. All data are shown as mean ± standard deviation, except for smoking history BMI Body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, HR heart rate, bpm beats per minute a P-value is based on non-parametric Mann-Whitney U-test b For each patient, median of three measurements is used to calculate mean peripheral blood pressure, early pulse wave reflections can boost the cSBP reflected by a positive AIx. Early pulse wave reflections are being recognized as an important factor that contributes to the increase in central blood pressure [42] . As AIx was negative with ritodrine, early wave reflections cannot contribute to the increase in cSBP during ritodrine, which is due to the beta-agonistic positive inotropic effect witnessed by the increase in heart rate. During ritodrine, there was also a rise in SBP at both the levels of the BA and the RA. This is not in accordance with other studies reporting a decrease in SBP taken sphygmomanometrically [3, 7, 31] . This difference can be explained by the fact that the subjects in those studies were pregnant. Pregnant women in premature labor have an already higher baseline SBP in comparison with the nonpregnant group. It may not be excluded that in those studies with pregnant women, the anxiety related to premature birth and the hospital setting artificially boosted SBP at the start of treatment. Finally, an altered effect of ritodrine in pregnant women cannot be fully excluded [43, 44] . The effect of atosiban on the SBP at the levels of the CCA, BA, or RA in our study was not significantly different from placebo, which is in accordance with other studies [3, 34] .
Blood pressure amplification
Mean and diastolic blood pressure hardly change in the large artery tree [24, 25] . In contrast, when early wave reflections are absent as in young subjects, a clear amplification of the systolic blood pressure from the heart to the periphery is present. This explains why blood pressure measured at the brachial artery may overestimate the pressure seen by the heart [45] . This pressure amplification is due to a gradual decrease in arterial compliance (C) from central to peripheral arteries [46] and can be influenced by pulse wave reflections [47] . For ritodrine, in contrast to atosiban and placebo, pressure amplification between the CCA and the upper limb is nearly absent (with a difference of only 2 mmHg between the CCA and the RA). This loss of pressure amplification with ritodrine can be explained by an increased arterial compliance, due to beta 2 -mediated vasodilatation [48] .
Study limitations and clinical implications
The present study was carried out in nonpregnant women. It is not clear whether the present results in nonpregnant women can be fully extrapolated to pregnant women. Physiologic changes during pregnancy such as an increase in cardiac output, a decrease in peripheral resistance [49, 50] , and modulation of oxytocin receptors during pregnancy [51, 52] may alter the magnitude of the pharmacodynamic effects. On the other hand, pain and stress during premature labor may also confound the effects of tocolytic drugs. To elucidate these issues, this study would ideally be performed in women in late pregnancy without signs of premature labor, but this may be difficult because of ethical issues.
Ritodrine has important but contradictory effects on the cardiovascular system. In the U.K., the Royal College of Obstetricians and Gynaecologists' guidelines on betamimetics recommend close monitoring of maternal pulse and blood pressure every 15 min during the infusion in every patient receiving a β-agonist as tocolyticum [7] . The fall in DBP, MAP, and AIx due to the relaxation of the vascular smooth muscle cells may appear an advantage in cases where the peripheral resistance is raised, as in gestational hypertension or preeclampsia. However, in hypertensive pregnancies, the circulating components of the RAAS (renin-angiotensin-aldosterone system) are decreased [53] . On the contrary, beta-agonists such as ritodrine may trigger the RAAS with enhanced renal sodium absorption resulting in vascular overfilling with increased risk of pulmonary edema and acute heart failure [54, 55] . In pregnant women with cardiovascular complications such as gestational hypertension, preeclampsia, and cardiomyopathies or in pregnant women with a history of cardiovascular complications during pregnancy, ritodrine may not be the first-line agent to control premature labor. Atosiban is then one of the alternatives.
In conclusion, the present study shows that the effects of ritodrine on blood pressure, blood pressure amplification, and pulse wave reflections are significantly different from atosiban and placebo. The present study clearly demonstrates the absence of those hemodynamic effects during atosiban infusion.
